-
N3-kethoxal for RNA and ssDNA Mapping
2026-09-09
N3-kethoxal is a membrane-permeable nucleic acid probe for labeling unpaired guanine in RNA and single-stranded DNA. Its azide handle supports bioorthogonal click chemistry labeling, while KAS-ATAC demonstrates how the probe can enrich accessible, ssDNA-containing genomic fragments.
-
Firefly Luciferase mRNA: Practical Assay Guide
2026-09-08
Firefly Luciferase mRNA (ARCA, 5-moUTP) provides a sensitive, non-destructive readout for delivery, translation, cell state, and formulation performance. This guide converts its cap, nucleotide modification, and poly(A) design into practical workflows for gene expression assays, cell viability assays, and in vivo imaging.
-
Angiotensin 1/2 (1-6): Assay Design and RAS Biology
2026-09-08
Explore how Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, supports mechanistic renin-angiotensin system research. This guide connects cardiovascular and renal assay design with emerging spike–receptor binding evidence while defining key experimental limitations.
-
Palonosetron for Chemotherapy-Induced Nausea and Vomiting
2026-09-07
Fabi and Malaguti review how palonosetron, a long-acting 5-HT3 receptor antagonist, improves prevention of acute and delayed chemotherapy-induced nausea and vomiting, with particular relevance to moderate-emetogenic chemotherapy. The paper’s main contribution is an integrated interpretation of pharmacology, clinical evidence, guideline placement, and remaining gaps such as multi-day chemotherapy.
-
Müller Cell PEDF and Retinal Neuron Survival
2026-09-05
The 2026 study by Younis and colleagues identifies a Müller cell–mediated pathway in which opposing Ang-1 and Ang-2 signals regulate Tie-2–PI3K/Akt activity, PEDF production, and retinal neuronal survival. Its co-culture, hypoxia, knockdown, and rescue experiments provide a framework for separating direct neuronal effects from glial-mediated neuroprotection and for evaluating pathway-selective perturbations.
-
Structure-Guided Proteomimetics Against SARS-CoV-2 Entry
2026-09-05
The reference study converts two human ACE2 recognition elements into constrained proteomimetics that engage the SARS-CoV-2 Spike receptor-binding domain and interfere with viral entry. Its lead construct, proteomimetic 28, combines structural fidelity with improved epithelial stability and low permeability, providing a useful framework for targeting broad, shallow protein–protein interfaces.
-
Cinoxacin in Gram-Negative Research Workflows
2026-09-04
Cinoxacin offers a practical, historically grounded way to model DNA-synthesis inhibition in susceptible Gram-negative urinary pathogens. This guide translates its MIC range, urinary pharmacokinetics, and spectrum limits into reproducible susceptibility, time-kill, and antibiotic resistance studies.
-
Grazoprevir Hydrate: HCV Assay Workflows
2026-09-04
Build reproducible HCV inhibition assays around Grazoprevir hydrate, from DMSO stock preparation to genotype-aware dose–response analysis. The workflow distinguishes biochemical target engagement from cell-based antiviral activity and shows how to extend single-agent testing into combination and resistance studies.
-
AICAR and Mitophagy: Designing AMPK Research
2026-09-03
AICAR enables controlled AMPK perturbation for studying energy metabolism regulation, mitochondrial quality control, and cellular stress protection. This article translates a 2025 skeletal-muscle mitophagy study into practical assay decisions without overstating what AICAR itself demonstrated.
-
TMAO, PERK Activation, and NAFLD in Zebrafish
2026-09-03
A 2024 Toxicology Letters study used controlled TMAO exposure in adult zebrafish to show that TMAO can directly produce hepatic steatosis, inflammation, injury, and fibrosis while activating PERK signaling. Its combination of an in vivo model with HepG2 and hepatic stellate cell experiments strengthens the link between TMAO, ER stress, and NAFLD, while leaving pharmacological causality to be tested directly.
-
SNAI1–PIK3R2/p-EphA2 Signaling in TETs
2026-09-02
The 2024 reference study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and preserves cancer stem cell-like properties in thymic epithelial tumors. By combining computational analysis, functional models, single-cell profiling, chromatin assays, protein-interaction studies, and phosphoproteomics, the authors connect SNAI1 to a PIK3R2/p-EphA2/GSK3β–β-catenin signaling axis with potential relevance for therapeutic research.
-
High-Throughput BBB Model: Hu et al. 2025
2026-09-02
Hu et al. developed a Transwell blood-brain barrier surrogate that pairs LLC-PK1-MOCK and LLC-PK1-MDR1 cells with lysosomal-trapping correction. Testing across 41 compounds linked MDR1-derived permeability with unbound brain distribution and provided a practical way to separate passive diffusion, P-glycoprotein efflux, and intracellular sequestration during early CNS drug screening.
-
Vorinostat in Neuroblastoma Assay Design
2026-09-01
Explore how Vorinostat and suberoylanilide hydroxamic acid can serve as mechanistic benchmarks in epigenetic oncology studies. This article translates recent neuroblastoma findings into practical decisions for chromatin, cell-cycle, apoptosis, and combination assays.
-
Quizartinib (AC220): From FLT3 Biology to Translation
2026-09-01
A thought-leadership framework for using Quizartinib (AC220) to connect FLT3 biology, assay design, resistance modeling, and translational strategy in acute myeloid leukemia research.
-
FASN, Mitochondrial Priming, and Navitoclax
2026-08-31
The reference study shows that fatty acid synthase inhibition does more than restrict tumor lipid production: it increases mitochondrial apoptotic priming through redox stress and BH3-only protein activation. This metabolic shift selectively strengthens the activity of ABT-263 (Navitoclax) and venetoclax, providing a mechanistic framework for combination studies in breast cancer models.